Sermorelin: the native signal, unmodified

The short version

Sermorelin is the first 29 amino acids of growth-hormone-releasing hormone — the natural signal the brain already sends the pituitary. Nothing about it has been redesigned. It is not protected against the enzymes that break peptides down, it does not bind albumin, and it lasts minutes rather than days.

That is deliberate, and it is the argument for it. Because the signal is the ordinary one and it disappears quickly, everything downstream stays in charge: somatostatin can still apply the brake, IGF-1 feedback still registers, and the pituitary sets the size of the pulse rather than the drug doing it ^[15].

Sermorelin is also the one compound on this site with a genuine regulatory past. It was a real, FDA-approved medicine for children who could not make enough growth hormone. It was taken off the US market in 2008 for commercial reasons — not because it was found unsafe or ineffective. It is not an approved marketed drug today, and it was not withdrawn for harm. Both halves of that sentence get misreported constantly.

Where the evidence is genuinely thin is the use it is most heavily marketed for: anti-aging and body composition in healthy adults.

What it is

Sermorelin acetate is an amidated synthetic 29-amino-acid peptide corresponding to the amino-terminal 1–29 fragment of endogenous human growth-hormone-releasing hormone, a 44-residue molecule. GHRH(1–29) is the shortest fragment that retains full activity at the GHRH receptor, which is a genuinely elegant piece of structure-activity biology: roughly a third of the molecule turns out to carry all of its signalling function.

It circulates in the literature as GHRH(1–29), GRF(1–29) and GRF(1–29)NH2. It is the parent structure that CJC-1295 modifies — CJC-1295 is hGRF(1–29) with four substitutions and, in the DAC form, an albumin hook — so the two compounds are best understood as the same signal with and without engineering.

The regulatory record, stated precisely. Sermorelin acetate was approved by the FDA as a branded product (NDA 020443) for idiopathic growth-hormone deficiency and short stature in children. It was withdrawn from the US market in 2008 for commercial reasons, not because of any safety or efficacy finding. It is therefore not currently a marketed FDA-approved drug, and it is not a drug pulled for harm — the two most common errors point in opposite directions. Today it is available through compounding pharmacies and is treated as a long-standing Category 1 bulk drug substance under the FDA's interim Section 503A policy, with final guidance issued in January 2025, meaning the agency does not intend enforcement action against Category 1 compounding. That situation is materially different from ipamorelin's and CJC-1295's, both of which went through Category 2 and Pharmacy Compounding Advisory Committee review; the three should not be lumped together. Like every compound on this site, sermorelin is prohibited in sport, and detection methods for GHRH analogues exist.

How it works: a signal that knows when to stop

Sermorelin binds the GHRH receptor on anterior-pituitary somatotrophs and activates the adenylate cyclase / cAMP / PKA cascade, stimulating both synthesis and pulsatile release of the body's own growth hormone. The 2025 Nature Reviews Endocrinology synthesis of GHRH biology covers that receptor signalling and the wider analogue landscape in depth ^[8].

Mechanistically the interesting property is what sermorelin lacks. It acts upstream, on the pituitary, rather than supplying growth hormone from outside — so the entire regulatory apparatus above and below the gland remains connected. Somatostatin tone still shapes when a pulse can occur. Rising IGF-1 still feeds back. The pituitary's own secretory capacity still sets the ceiling. An editorial arguing for sermorelin in adult-onset growth-hormone insufficiency makes exactly this case: a physiologic secretagogue that preserves pulsatile release and pituitary feedback may be a better-shaped intervention than recombinant growth hormone, which simply floods the system and switches the feedback loop off ^[15].

It is worth being scrupulous about the status of that claim. It is an editorial argument grounded in mechanism, not the result of a head-to-head trial against recombinant growth hormone. It is a good argument. It has not been tested as a clinical hypothesis.

There is a further wrinkle that belongs on a site about pulsatility. The GHRH pathway is built to be pressed intermittently, not continuously. When GHRH(1–29) was administered as a non-stop continuous infusion in children, the growth-hormone response faded over months of exposure, in some cases to the point of suppression. Pulsatile input is not a stylistic preference of the axis; it is a condition of the axis continuing to respond at all — which is why GHRH peptides are studied as intermittent signals and why the CJC-1295 result showing preserved pulsatility under multi-day stimulation was not a foregone conclusion.

What the research shows

The controlled pediatric outcome. In a multicentre trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1–29) accelerated linear growth, with first-year height velocity rising from about 4.1 cm/year to roughly 7–8 cm/year, and without excessive IGF-1 generation ^[16]. This is the strongest evidence on this page and one of the strongest on this site, because height velocity is a real clinical outcome rather than a hormone reading — and because "without excessive IGF-1 generation" is the pulsatility argument showing up as a measurable result rather than a talking point.

The cognition trial that is nearly always misattributed. A randomised, double-blind, placebo-controlled trial in 152 older adults, 66 of them with mild cognitive impairment, found that 20 weeks of a daily subcutaneous GHRH analogue at bedtime had a favourable effect on cognition (P=0.03, with executive function at P=0.005), increased IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4%, with mild adverse events ^[13]. This trial is routinely cited on wellness sites as evidence for sermorelin. It is not. The peptide administered was tesamorelin, a different GHRH analogue. It is legitimate read-across evidence for what GHRH-receptor stimulation can do in older adults; it is not sermorelin data, and any page presenting it as such is misreading its own source.

The class-level caution, from a serious venue. An Annals of Internal Medicine editorial reviewing the use of growth-hormone secretagogues to prevent or treat the effects of aging concluded that the practice is not yet justified by the evidence — its title, "not yet ready for prime time," is the summary ^[14]. That editorial predates none of the marketing built on top of it, and nothing published since has retired it.

The physiologic-approach argument. The editorial case for sermorelin as a more physiologic route to adult-onset growth-hormone insufficiency than recombinant growth hormone ^[15] is the intellectual foundation of essentially every adult sermorelin protocol in circulation. It is an argument, published as an argument.

Read as a whole, the evidence stack is lopsided in a specific way. Sermorelin has a real controlled outcome in a pediatric deficiency population ^[16] and a coherent mechanistic case ^[15][8]. What it does not have is a controlled trial of the thing it is overwhelmingly sold for: sustained anti-aging, fat-loss or vitality benefit in healthy adults. Where evidence for that use is offered, it is usually surrogate (IGF-1 went up), borrowed from a different analogue ^[13], or anecdotal.

Reported effects, cautions and safety

The following community record is anecdotal, not clinical evidence — patient testimonials, forum accounts and clinic write-ups summarising what people say about themselves, with no verification and no controls. Deeper, more restful sleep with markedly more vivid dreams is very commonly the reason people say they tried it, and often reported within the first fortnight. More daytime energy and a sense of easier recovery is frequently reported, usually credited to the sleep rather than to any stimulant effect. Gradual loss of body fat over a few months is frequently reported and heavily confounded by concurrent diet and exercise. Better muscle tone, firmer skin and general well-being are occasionally reported and are the least separable from ordinary lifestyle effects. One recurring theme is worth recording precisely because it cuts against the marketing: many accounts describe sermorelin as a slow burn where the first month feels like nothing is happening, with change appearing — if at all — in the second or third month. On the adverse side, mild injection-site redness, itching or swelling is the most common complaint by a wide margin; short-lived headache, flushing, dizziness or mild nausea in the first week or two is frequently reported; water retention or puffiness, increased appetite and post-dose drowsiness are occasionally reported; tingling or numbness in the hands and small rises in blood sugar in predisposed people are reported rarely.

The cited and mechanistic cautions:

The anti-aging case is not proven, and a major journal said so. Sermorelin is marketed hard for anti-aging, fat loss and vitality, and the long-term trials that would support those uses do not exist. The Annals of Internal Medicine editorial judging growth-hormone-secretagogue use for aging "not yet ready for prime time" remains the appropriate calibration ^[14]. Strong wellness claims about this compound should be treated as claims.

Chronically raising growth hormone and IGF-1 carries a theoretical cancer concern. Both are mitogenic, so deliberately elevating them over long periods raises a proliferation question that applies to any growth-hormone-axis intervention ^[8]. Sermorelin's feedback-controlled, pulsatile route may temper how high IGF-1 climbs — the pediatric trial explicitly reported growth acceleration without excessive IGF-1 generation ^[16] — but "may temper" is not "resolves", and no long-term human data settles it.

Glucose tolerance deserves monitoring, particularly with age. Growth hormone opposes insulin, so raising it can push blood sugar up in susceptible people. Repeated dosing of a long-acting GHRH peptide has been linked to some impairment of glucose tolerance in elderly subjects. Older, prediabetic or metabolic-syndrome physiology is where this matters most.

Injection-site reactions and small metabolic shifts are the consistent findings. Across human studies of GHRH(1–29) and related peptides, mild injection-site irritation is the most reproducible adverse effect, alongside transient changes such as a temporary rise in blood lipids that resolved. Mild and reversible — but evidence that the body responds beyond the intended target.

The pituitary is not a single switch. In a study of short children, an intravenous dose of GHRH(1–29) produced small, short-lived rises in other pituitary hormones — prolactin, LH and FSH. The effect was minor. It is still a reminder that selectivity at a receptor is not the same as isolation of an organ.

Continuous exposure blunts the response. As above: round-the-clock GHRH(1–29) infusion in children saw the growth-hormone response fade over months. This is the strongest practical argument on the site for why intermittent signalling is not merely aesthetic.

Gray-market supply is a real variable. Much sermorelin sold outside the pharmacy chain comes from a largely unregulated market, where critical reviews report frequent mislabelling and contamination and scarce rigorous human safety data for unapproved use. Oral, sublingual and troche "sermorelin" products draw particular criticism, since peptides are degraded in the gut and absorbed poorly across mucosa — consistent with the very low intranasal bioavailability reported for GHRH(1–29).

Where it fits in the growth hormone axis

Sermorelin is the control condition for this entire category. It is what the GHRH signal does when nobody engineers it — minutes long, fully feedback-braked, pulse shape determined by the pituitary rather than by pharmacokinetics. Every other GHRH compound here is a modification of it, and the sensible way to read CJC-1295 is as sermorelin with the clock stretched ^[19].

Its evidence profile is the mirror image of ipamorelin's. Ipamorelin has striking mechanism and a failed human efficacy trial ^[3]. Sermorelin has a modest mechanism story and a successful controlled human outcome ^[16] — in a population almost nobody buying it today belongs to. The gap between the pediatric-deficiency evidence and the adult-vitality marketing is where nearly all the confusion about this compound lives, and it is not a gap mechanism can close.

Next: what happens when the unmodified GHRH signal, the engineered one and the ghrelin-side trigger are combined — CJC-1295 / Ipamorelin — or compare these peptides side by side.